ANDA 218442, held by Biocon Pharma Ltd. Oxcarbazepine.
As of Nov 16, 2026, ANDA 218442 (Oxcarbazepine), held by Biocon Pharma Ltd, was not approved, with 0 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jan 8, 2025 | Original application | Tentative approval | None posted |
| Oxcarbazepine300MG · tablet;extended release | Oxcarbazepine | None (tentative approval) |
| Oxcarbazepine600MG · tablet;extended release | Oxcarbazepine | None (tentative approval) |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters